Analysts forecast that Bausch Health Companies Inc. (NYSE:BHC – Get Rating) will report sales of $2.09 billion for the current quarter, according to Zacks. Four analysts have provided estimates for Bausch Health Companies’ earnings, with estimates ranging from $2.01 billion to $2.13 billion. Bausch Health Companies posted sales of $2.10 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.5%. The business is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Bausch Health Companies will report full-year sales of $8.45 billion for the current fiscal year, with estimates ranging from $8.31 billion to $8.57 billion. For the next financial year, analysts expect that the business will report sales of $8.76 billion, with estimates ranging from $8.66 billion to $8.85 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Bausch Health Companies.
Bausch Health Companies (NYSE:BHC – Get Rating) last released its quarterly earnings data on Wednesday, February 23rd. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.19. The business had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Bausch Health Companies had a negative return on equity of 649.29% and a negative net margin of 4.89%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.33 EPS.
NYSE:BHC opened at $9.93 on Monday. The stock’s 50 day moving average price is $19.66 and its 200 day moving average price is $23.34. The company has a market capitalization of $3.58 billion, a PE ratio of -8.71, a P/E/G ratio of 0.22 and a beta of 1.62. Bausch Health Companies has a 52-week low of $7.80 and a 52-week high of $32.54.
In other news, insider Robert Spurr sold 4,846 shares of the firm’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $22.20, for a total value of $107,581.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph F. Gordon sold 6,338 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $23.82, for a total value of $150,971.16. The disclosure for this sale can be found here. Insiders sold a total of 16,668 shares of company stock valued at $378,570 over the last three months. Insiders own 13.75% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amplius Wealth Advisors LLC purchased a new position in Bausch Health Companies in the 4th quarter valued at approximately $30,000. Glassman Wealth Services increased its stake in Bausch Health Companies by 71.4% in the 4th quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock valued at $32,000 after purchasing an additional 480 shares in the last quarter. WASHINGTON TRUST Co purchased a new position in Bausch Health Companies in the 1st quarter valued at approximately $28,000. Creative Financial Designs Inc. ADV increased its stake in Bausch Health Companies by 525.0% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock valued at $29,000 after purchasing an additional 1,050 shares in the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Bausch Health Companies in the 3rd quarter valued at approximately $228,000. 73.38% of the stock is owned by hedge funds and other institutional investors.
About Bausch Health Companies (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.